According to the NCI website, volitinib (savolitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Check for active clinical trials using this agent. (NCI Thesaurus)

More Information in English:

Link to Drug Information Portal, a service of the U.S. National Library of Medicine, National Institutes of Health
Link to National Cancer Institute

Wiki